Abstract
Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. Antidepressant dugs are still clinically used and industrially designed on the basis of the monoaminergic theory. Recent developments regarding selective monoaminergic uptake inhibitors can further improve the safe and rational treatment for patients with depression. However, monoamine-based antidepressants may cause unfavorable and incomplete remission of a considerable number of patients with depression; therefore, development of new antidepressant drugs based on other mechanisms is required. Meanwhile, there has been an impressive accumulation of knowledge about cytokines that might contribute to the understanding of the pathophysiology of depression. Therefore, this review focuses on the association between depressive disorder and cytokines and discusses the strategies for developing new cytokine-based antidepressant drugs.
Keywords: Depressive disorder, antidepressant, cytokine, interleukin, interferon, sickness behavior
Current Pharmaceutical Design
Title: New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways
Volume: 15 Issue: 14
Author(s): Akira Nishida, Tsuyoshi Miyaoka, Takuji Inagaki and Jun Horiguchi
Affiliation:
Keywords: Depressive disorder, antidepressant, cytokine, interleukin, interferon, sickness behavior
Abstract: Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. Antidepressant dugs are still clinically used and industrially designed on the basis of the monoaminergic theory. Recent developments regarding selective monoaminergic uptake inhibitors can further improve the safe and rational treatment for patients with depression. However, monoamine-based antidepressants may cause unfavorable and incomplete remission of a considerable number of patients with depression; therefore, development of new antidepressant drugs based on other mechanisms is required. Meanwhile, there has been an impressive accumulation of knowledge about cytokines that might contribute to the understanding of the pathophysiology of depression. Therefore, this review focuses on the association between depressive disorder and cytokines and discusses the strategies for developing new cytokine-based antidepressant drugs.
Export Options
About this article
Cite this article as:
Nishida Akira, Miyaoka Tsuyoshi, Inagaki Takuji and Horiguchi Jun, New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways, Current Pharmaceutical Design 2009; 15 (14) . https://dx.doi.org/10.2174/138161209788168065
DOI https://dx.doi.org/10.2174/138161209788168065 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In silico Structural and Functional Analysis of Arabidopsis thaliana’s XPB Homologs
Current Proteomics Induction of Apoptosis by Curcumin and Its Implications for Cancer Therapy
Current Cancer Drug Targets T-Cells and B-Cells in Systemic Sclerosis
Current Rheumatology Reviews The Hyperforin Derivative IDN5706 Occludes Spatial Memory Impairments and Neuropathological Changes in a Double Transgenic Alzheimers Mouse Model
Current Alzheimer Research Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone/Mineralocorticoid Receptor System
Current Diabetes Reviews Laboratory Studies and Clinical Trials on New Formulations from Garlic Extract Against Cutaneous Leishmaniasis
Anti-Infective Agents Neuroimaging of Gut Nutrient Perception
Current Pharmaceutical Design To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Atypical Neurotransmitters and the Neurobiology of Depression
CNS & Neurological Disorders - Drug Targets Treatment of Graves Hyperthyroidism with Thionamides-Derived Drugs: Review
Medicinal Chemistry New Drug Targets for Hepatitis C and Other Flaviviridae Viruses
Infectious Disorders - Drug Targets Synergy Against Fungal Pathogens: Working Together is Better Than Working Alone
Current Medicinal Chemistry Targeting Strategies to Modulate the NF-κB and JNK Signal Transduction Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Consideration of Cytokines as Therapeutics Agents or Targets
Current Pharmaceutical Design Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Endotoxin-Neutralizing Peptides as Gram-Negative Sepsis Therapeutics
Protein & Peptide Letters Probiotics for the Prevention and Treatment of Allergies, with an Emphasis on Mode of Delivery and Mechanism of Action
Current Pharmaceutical Design Diacylglycerol Kinase Inhibition and Vascular Function
Current Enzyme Inhibition Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry IRAKs: Key Regulatory Kinases of Innate Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents